Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/198312VIRAL INFECTIONS- TREATMENT WITH CONVALESCENT PLASMA/SERUM
WO 07.10.2021
Int.Class A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Appl.No PCT/EP2021/058383 Applicant REGEN LAB SA Inventor TURZI, Antoine
A container for use in the treatment and/or prophylaxis of viral infections and/or associated conditions prefilled with a thixotropic gel characterized by a density selected from about 1.02 g/cm3 to about 1.05 g/cm3.
2.2024205654Viral infections- treatment with convalescent plasma/serum
AU 22.08.2024
Int.Class A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Appl.No 2024205654 Applicant Regen Lab SA Inventor GOMRI, Farid
VIRAL INFECTIONS - TREATMENT WITH CONVALESCENT PLASMA/SERUM A container for use in the treatment and/or prophylaxis of viral infections and/or associated conditions prefilled with a thixotropic gel characterized by a density selected from about 1.02 g/cm3 to about 1.05 g/cm 3.
3.2021249444Viral infections- treatment with convalescent plasma/serum
AU 07.10.2021
Int.Class A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Appl.No 2021249444 Applicant Regen Lab SA Inventor GOMRI, Farid
A container for use in the treatment and/or prophylaxis of viral infections and/or associated conditions prefilled with a thixotropic gel characterized by a density selected from about 1.02 g/cm3 to about 1.05 g/cm3.
4.WO/2021/203034ALIMENTARY AND SYSTEMIC ANTIVIRAL THERAPEUTICS
WO 07.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/025630 Applicant FIREBREAK, INC. Inventor STARZL, Timothy, W.
Methods and compositions are provided for rapid preparation of anti-SARS- CoV-2 protein polyclonal IgY antibodies. Compositions comprising the antibodies are useful for decreasing transmission, duration, and/or severity of coronavirus disease 2019 (COVID-19). Lingual and sublingual alimentary traps, oral, parenteral, and inhalable compositions are provided for preventing and treating COVID-19. The compositions can be rapidly tailored for seasonal or even monthly mutations in the SARS-CoV-2 viral antigenic proteins. Improved methods of generating IgY antibodies are also provided.
5.WO/2022/120375POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION
WO 09.06.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2021/072723 Applicant THE UNIVERSITY OF CHICAGO Inventor WILSON, Patrick
To address the need in the art, the inventors have comprehensively characterized the SARS-CoV-2-specific B cell repertoire in convalescent COVID-19 patients and generated mAbs against the spike, ORF8, and NP proteins. Together, the inventors' data reveal key insight into antigen specificity and B cell subset distribution upon SARS-CoV-2 infection in the context of age, sex, and disease severity. Aspects of the disclosure relate to novel antibody and antigen binding fragments. Further aspects relate to polypeptides comprising the antigen binding fragment(s) of the disclosure, and compositions comprising the polypeptides, antibodies, and/or antigen binding fragments of the disclosure. Also described are nucleic acids encoding an antibody or antigen binding fragment of the disclosure.
6.4509529ANTIBODY USED TO TREAT CORONAVIRUS INFECTION
EP 19.02.2025
Int.Class C07K 16/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40against enzymes
Appl.No 23788361 Applicant RIKEN Inventor SAITO TAKASHI
The present invention provides an antibody that binds to an extracellular domain of TMPRSS2, capable of inhibiting beta coronavirus infection of cells, or an antigen-binding fragment thereof, and a composition including the antibody or an antigen-binding fragment thereof.
7.WO/2021/216738COMPOSITIONS AND METHODS OF GENERATING AN IMMUNE RESPONSE
WO 28.10.2021
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No PCT/US2021/028436 Applicant INTIMA BIOSCIENCE, INC. Inventor HENLEY, Thomas
Provided herein are compositions and methods for use in generating an immune response against a target peptide antigen. Also included, are methods for stabilizing, treating, and eliminating various diseases and conditions associated with target peptide expression.
8.WO/2022/126119METHODS AND SYSTEMS FOR DETECTION AND ANALYSIS OF ANGIOTENSIN BINDING ANTIBODIES
WO 16.06.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/072823 Applicant THE UNIVERSITY OF CHICAGO Inventor SWARTZ, Melody
Aspects of the disclosure are directed to methods, systems, and compositions for detecting antibodies capable of binding to angiotensin II. Certain aspects comprise detection of antibodies capable of binding to angiotensin II in a sample from a subject, where the subject has or has had a coronavirus infection, such as a SARS-CoV-2 infection. Also disclosed are vaccine compositions comprising a portion of SARS-CoV-2 Spike protein, where such compositions do not induce generation of angiotensin Il-binding antibodies.
9.3175533ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME
CA 21.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 3175533 Applicant VIR BIOTECHNOLOGY, INC. Inventor CORTI, DAVIDE
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, the presently disclosed antibodies are capable of binding to S proteins of multiple sarbecoviruses and/or neutralizing infection by multiple sarbecoviruses. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus infection, such as a SARS-CoV-2 infection.
10.WO/2022/094622POLYPEPTIDES FOR DETECTION AND TREATMENT OF SARS-COV-2
WO 05.05.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/072152 Applicant THE UNIVERSITY OF CHICAGO Inventor KOSSIAKOFF, Anthony
Aspects of the present disclosure relate to polypeptides that specifically bind to a SARS-CoV-2 spike protein, and to methods of use for treatment, prevention, and diagnosis of a SARS-CoV-2 infection. Certain aspects are directed to antibodies and fragments thereof, including Fabs, configured to bind to various epitopes within the receptor binding domain (RBD) of a SARS-CoV-2 spike protein. Compositions, kits, and methods for detection of SARS-CoV-2 are also disclosed.